



## Update on New Zealand standardised batch sheets for compounded oral liquid formulations – November 2019



HEALTH QUALITY & SAFETY  
COMMISSION NEW ZEALAND  
*Kupu Taurangi Hauora o Aotearoa*

### Updates on Amiodarone and Amlodipine Standardised Batch Sheets

As at 15<sup>th</sup> November 2019, the HQSC Compounding Working Group has updated two of the NZ standardised batch sheets for oral liquid formulations (NZSOF) that are hosted on the PSNZ website as follows:

1. **Amiodarone** – This sheet has been updated to include the Aratac brand of amiodarone.  
The funded brand of amiodarone tablets has changed from Cordarone-X to Aratac. Cordarone-X will be delisted from 1 December 2019. We have established that the suspension compounded with the Aratac brand of amiodarone is visually physically stable with no detectable change in suspension characteristics.
2. **Amlodipine** – Following feedback regarding clumping Ora-Sweet is now the only recommended suspending agent for amlodipine suspension.  
The old batch sheet allowed compounding in Ora-Sweet or Ora-Sweet SF (sugar free). Feedback from a community pharmacy highlighted stability problems (clumping) with the current funded brand of amlodipine (Apo-amlodipine) and the Ora-Sweet SF. The formulation has therefore been amended to **Ora-Sweet** only.

**Dave Woods, Billy Allan, Chloë Campbell**

*on behalf of the Compounding Working Group, 15 November 2019*